Suppr超能文献

相似文献

1
Emerging Tim-3 functions in antimicrobial and tumor immunity.
Trends Immunol. 2011 Aug;32(8):345-9. doi: 10.1016/j.it.2011.05.003. Epub 2011 Jun 21.
2
T cell immunoglobulin-3 as a new therapeutic target for rheumatoid arthritis.
Expert Opin Ther Targets. 2012 Dec;16(12):1145-9. doi: 10.1517/14728222.2012.726616. Epub 2012 Sep 22.
3
TIM-3 in autoimmunity.
Curr Opin Immunol. 2006 Dec;18(6):665-9. doi: 10.1016/j.coi.2006.09.009. Epub 2006 Oct 2.
4
The role of T cell immunoglobulin and mucin domain-3 in immune thrombocytopenia.
Scand J Immunol. 2014 Apr;79(4):231-6. doi: 10.1111/sji.12153.
6
Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells.
J Immunol. 2010 Aug 1;185(3):1383-92. doi: 10.4049/jimmunol.0903275. Epub 2010 Jun 23.
8
Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C.
PLoS Pathog. 2013;9(6):e1003422. doi: 10.1371/journal.ppat.1003422. Epub 2013 Jun 20.
9
The Tim-3/galectin-9 pathway involves in the homeostasis of hepatic Tregs in a mouse model of concanavalin A-induced hepatitis.
Mol Immunol. 2014 Mar;58(1):85-91. doi: 10.1016/j.molimm.2013.11.001. Epub 2013 Dec 10.

引用本文的文献

1
Molecular pathology of lymphoma and its treatment strategies: from mechanistic elucidation to precision medicine.
Front Immunol. 2025 Jul 9;16:1620895. doi: 10.3389/fimmu.2025.1620895. eCollection 2025.
2
TIM3 and TIGIT-expressing CD4 T cells are impacted by kidney transplantation and associated with risk of infection.
Front Immunol. 2025 May 22;16:1550154. doi: 10.3389/fimmu.2025.1550154. eCollection 2025.
3
4
Radioresistance Mechanisms in Head and Neck Cancer.
Clin Exp Otorhinolaryngol. 2025 Aug;18(3):210-224. doi: 10.21053/ceo.2025-00029. Epub 2025 Apr 23.
6
Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy.
Ther Adv Vaccines Immunother. 2024 Oct 9;12:25151355241288453. doi: 10.1177/25151355241288453. eCollection 2024.
7
A potential defensive role of TIM-3 on T lymphocytes in the inflammatory involvement of diabetic kidney disease.
Front Immunol. 2024 May 15;15:1365226. doi: 10.3389/fimmu.2024.1365226. eCollection 2024.
8
Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion.
Exp Hematol Oncol. 2024 Apr 12;13(1):39. doi: 10.1186/s40164-024-00505-7.
9
Do galectins serve as soluble ligands for immune checkpoint receptors?
J Immunother Cancer. 2024 Apr 9;12(4):e008984. doi: 10.1136/jitc-2024-008984.
10
Neonatal CD8+ T Cells Resist Exhaustion during Chronic Infection.
J Immunol. 2024 Mar 1;212(5):834-843. doi: 10.4049/jimmunol.2300396.

本文引用的文献

1
Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors.
Cancer Res. 2011 May 15;71(10):3540-51. doi: 10.1158/0008-5472.CAN-11-0096. Epub 2011 Mar 23.
2
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.
Blood. 2011 Apr 28;117(17):4501-10. doi: 10.1182/blood-2010-10-310425. Epub 2011 Mar 8.
4
Tim3 binding to galectin-9 stimulates antimicrobial immunity.
J Exp Med. 2010 Oct 25;207(11):2343-54. doi: 10.1084/jem.20100687. Epub 2010 Oct 11.
5
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
J Exp Med. 2010 Sep 27;207(10):2187-94. doi: 10.1084/jem.20100643. Epub 2010 Sep 6.
7
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection.
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14733-8. doi: 10.1073/pnas.1009731107. Epub 2010 Aug 2.
9
Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells.
J Immunol. 2010 Aug 1;185(3):1383-92. doi: 10.4049/jimmunol.0903275. Epub 2010 Jun 23.
10
Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response.
PLoS Pathog. 2010 May 6;6(5):e1000882. doi: 10.1371/journal.ppat.1000882.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验